Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. [electronic resource]
Producer: 20190409Description: 671-676 p. digitalISSN:- 1538-8514
- Adult
- Aged
- Anemia -- chemically induced
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- CTLA-4 Antigen -- immunology
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Exanthema -- chemically induced
- Female
- Humans
- Ipilimumab -- administration & dosage
- Lenalidomide -- administration & dosage
- Male
- Middle Aged
- Neoplasms -- classification
- Outcome Assessment, Health Care -- methods
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.